Quantum BioPharma Wins FDA Clearance for Phase 2 Multiple Sclerosis Trial of Lucid-MS

Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to initiate a Phase 2 clinical trial of Lucid-MS in patients with multiple sclerosis. The announcement, which drew editorial coverage from BioMedWire, positions Quantum BioPharma among a growing cohort of biopharmaceutical companies advancing novel neurological therapies and could signal a new direction in MS treatment.

The FDA clearance allows Quantum BioPharma to proceed with a randomized, double-blind, placebo-controlled Phase 2 study of Lucid-MS, also known as Lucid-21-302. Unlike many existing MS therapies that broadly suppress the immune system, Lucid-MS is designed to inhibit peptidyl arginine deiminase 2, or PAD2, and specifically target demyelination—the process by which the protective myelin sheath around nerve fibers is damaged, leading to the neurological symptoms of MS. This mechanism represents a first-in-class approach that could address an underlying cause of the disease rather than simply managing its inflammatory component.

The significance of this FDA clearance extends beyond a single company milestone. For patients with multiple sclerosis, current treatment options often come with significant side effects and do not directly repair or protect myelin. A therapy that prevents and reverses myelin degradation could potentially slow or halt disease progression in a way that existing immunomodulatory drugs cannot. Quantum BioPharma has reported that Lucid-MS previously completed Phase 1 testing in healthy volunteers with favorable safety and tolerability results, providing a foundation for the upcoming Phase 2 trial in people with MS.

In parallel, Quantum BioPharma is collaborating with scientists at Massachusetts General Hospital and Harvard Medical School on research involving a PET imaging tracer designed to quantify demyelination. This collaboration could yield a valuable biomarker tool for assessing treatment response in MS trials and eventually in clinical practice, further strengthening the company's position in the neuroinflammatory disease space.

Analyst attention has followed the regulatory progress. Rodman & Renshaw recently initiated coverage on Quantum BioPharma with a Buy rating and an $8 price target, reflecting confidence in the company's pipeline as it prepares Lucid-MS for its first clinical testing in people with MS. The BioMedWire editorial also placed Quantum BioPharma alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology, and neurological diseases.

Quantum BioPharma describes itself as a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS. The company also invented UNBUZZD and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.

For investors, the FDA clearance de-risks a key regulatory hurdle and sets the stage for clinical data that could validate the PAD2 inhibition approach. The Phase 2 trial will be closely watched as an indicator of whether Lucid-MS can offer a meaningful new option for multiple sclerosis patients. The company's newsroom is available at https://ibn.fm/QNTM, and the full press release can be viewed at https://ibn.fm/cwPHa.